Amylin- and calcitonin-receptor engagement by cagrilintide
Cagrilintide is a long-acting amylin analog whose molecular research focuses on calcitonin-receptor complexes, receptor-activity-modifying proteins, and signaling selectivity.
Overview
Cagrilintide is derived from an amylin-family peptide scaffold. Amylin receptors are formed when the calcitonin receptor associates with receptor-activity-modifying proteins, creating multiple receptor complexes with distinct ligand-recognition profiles.
Recent structural work has resolved cagrilintide bound to active amylin-receptor and calcitonin-receptor complexes. These studies compare contact patterns, receptor dynamics, and Gs-coupled activation across receptor subtypes. Broader amylin-receptor research provides the framework for interpreting those differences.
The most defensible VIVO story is receptor architecture and comparative signaling. It does not mean a VIVO material was evaluated in the cited work, and the sources do not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
References
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.
- Cao J, et al. (2025). Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications. View source ↗
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews; 67(3):564–600. View source ↗
- Bower RL, Hay DL (2016). Amylin structure–function relationships and receptor pharmacology. British Journal of Pharmacology; 173(12):1883–1898. View source ↗